Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.
Wei WangYisen HuangJianqiao KongLin LuQianxiu LiaoJingtao ZhuTinghao WangLinghua YanMin DaiZhan ChenJun YouPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
Our study highlights the importance of analyzing both tissue and plasma for detecting actionable mutations in CRC, with plasma ctDNA offering added value. Discordance is associated with gender and peritoneal metastases, and TMB analysis can benefit from a combination of tissue and plasma data. This approach provides valuable insights for personalized CRC treatment.